Medium-chain fatty acid mixed structure fat, preparation thereof and application of medium-chain fatty acid mixed structure fat in improvement of abundance of dunaliella

By preparing and adding medium-chain fatty acid mixed structural lipids, the abundance of Ducerella in the intestines is improved, and the intestinal flora disorders and systemic inflammation caused by a long-term high-fat diet is solved, and long-term improvements in intestinal health and inflammation are achieved. Significantly reduced.

CN118985774APending Publication Date: 2024-11-22HANGZHOU LONGYU BIO TECH CO LTD +1

Patent Information

Application Number
CN202411060264.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Long-term high-fat diet leads to intestinal flora disorders, destroys microecology, and causes systemic inflammation, metabolic disorders and other health problems. The existing structural lipid research focuses on transient flora changes, which has failed to effectively improve the abundance of the beneficial intestinal bacteria Dubaili and improve inflammation in the long term.

Method used

Prepare a medium-chain fatty acid mixed structural lipid containing triglyceride laurate and diglyceride laurate capric acid, with a molar ratio of 1:4-4:1, synthesized by esterification reaction, and added to high-fat feed to Increase the abundance of Duceriana in the intestinal flora and improve systemic inflammation.

Benefits of technology

In 16 weeks, it significantly increased the abundance of Ducerella in the intestinal region, reduced systemic inflammation induced by a high-fat diet, improved the microbial environment of the intestinal flora, reduced the level of inflammatory factors, and improved the expression of inflammatory genes in the liver.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004977651840000061
    Figure BDA0004977651840000061
  • Figure BDA0004977651840000071
    Figure BDA0004977651840000071
  • Figure BDA0004977651840000072
    Figure BDA0004977651840000072
Patent Text Reader

Abstract

The invention discloses medium-chain fatty acid mixed structure grease as well as preparation and application thereof in improvement of abundance of dunaliella. The medium-chain fatty acid mixed structure grease contains capric acid-lauric acid triglyceride and capric acid-lauric acid diglyceride, the molar ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structure grease is (1: 4)-(4: 1). According to the invention, a novel mixed structure fat is prepared, and it is found that the mixed structure fat can be used for regulating intestinal flora disorder and systemic inflammation induced by high fat, and especially has a remarkable effect on improvement of the abundance of dunaliella in intestinal flora.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of functional structured lipids, and in particular to a medium-chain fatty acid mixed structured lipid, its preparation, and its use in increasing the abundance of Ducromatium. Background Art

[0002] The intestinal flora and its metabolites achieve bidirectional signal transduction between the intestine and other tissues through the gut-brain axis, gut-liver axis and gut-heart axis. More and more studies have shown that a healthy and stable intestinal flora plays an important role in maintaining the health of the body. Long-term high-fat diet can lead to intestinal flora disorders, destroy the intestinal microecology, cause systemic inflammation, metabolic disorders and other problems, and affect the health of the body. Dunaliella is a beneficial intestinal bacterium that has physiological effects such as improving sugar and lipid metabolism, anti-aging, and improving hypertension.

[0003] Structural lipids are new functional lipids that modify glycerides by biological, chemical and other means to change their fatty acid composition and distribution. Studies have shown that structural lipids have a positive effect on reducing fat accumulation and improving sugar and lipid metabolism. The Chinese invention patent application document with publication number CN114907209A discloses a method for preparing a breast milk OMO type structural lipid (1,3-dioleic acid-2-medium chain saturated fatty acid glyceride), and synthesizes LML (long-medium-long chain) type structural lipids. The Chinese invention patent application document with publication number CN116179381A discloses a genetically engineered bacterium that produces OPO type structural esters and its construction method and application. A genetically engineered bacterium that produces OPO type structural lipids was constructed by genetic engineering means, and it can produce LLL (long-long-long chain) type structural lipids. The Chinese invention patent application document with publication number CN113768047A discloses a method for preparing a MSM (medium-short-medium chain) type butyrate-laurate mixed structural lipid and its regulatory effect on intestinal microorganisms. The application mainly studies the digestion of structural lipids and the sustained release of fatty acids, focusing on transient changes in intestinal flora (24 hours). Summary of the invention

[0004] The present application prepares a new mixed structural lipid, and finds that the mixed structural lipid can increase the abundance of Bacillus in the intestinal flora and improve systemic inflammation induced by a high-fat diet under long-term action (16 weeks). Based on this, the present application provides a medium-chain fatty acid mixed structural lipid, its preparation, and its use in increasing the abundance of Bacillus.

[0005] The present application provides an application of a medium-chain fatty acid mixed structured fat in the preparation of a feed for improving systemic inflammation caused by a high-fat feed, wherein the medium-chain fatty acid mixed structured fat contains capric lauric acid triglyceride and capric lauric acid diglyceride; the molar ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structured fat is 1:4-4:1.

[0006] The present application also provides an application of a medium-chain fatty acid mixed structure fat in the preparation of a feed for improving the microbial environment of intestinal flora, wherein the medium-chain fatty acid mixed structure fat contains capric lauric acid triglyceride and capric lauric acid diglyceride; the molar ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structure fat is 1:4-4:1.

[0007] The present application also provides an application of a medium-chain fatty acid mixed structure fat in the preparation of a feed for increasing the abundance of D. cerevisiae in intestinal flora, wherein the medium-chain fatty acid mixed structure fat contains capric lauric acid triglyceride and capric lauric acid diglyceride; the molar ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structure fat is 1:4-4:1.

[0008] Optionally, the capric lauric acid triglyceride is selected from at least one of 1,2-dicapric acid-3-lauric acid glyceride, 1,3-dicapric acid-2-lauric acid glyceride, 1-capric acid-2,3-dilauric acid glyceride and 1,3-dilauric acid-2-capric acid-glyceride; the capric lauric acid diglyceride is selected from at least one of 1-capric acid-3-lauric acid glyceride, 1-capric acid-2-lauric acid glyceride and 2-capric acid-1-lauric acid glyceride.

[0009] Optionally, the capric lauric acid triglyceride is a mixture of 1,3-dilauryl-2-capric acid-glyceride and 1,3-dicapryl-2-lauryl glyceride; the capric lauric acid diglyceride is 1-capryl-3-lauryl glyceride.

[0010] Optionally, the medium-chain fatty acid mixed structure fat is added to a high-fat feed at 100-3000 mg / kg. Further, the medium-chain fatty acid mixed structure fat is added to a high-fat feed at 150-2000 mg / kg, and further, the medium-chain fatty acid mixed structure fat is added to a high-fat feed at 200-1500 mg / kg.

[0011] The present application also provides a medium-chain fatty acid mixed structure fat, which contains capric lauric acid triglyceride and capric lauric acid diglyceride; the ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structure fat is 1:4-4:1.

[0012] Optionally, the capric lauric acid triglyceride is selected from at least one of 1,2-dicapric acid-3-lauric acid glyceride, 1,3-dicapric acid-2-lauric acid glyceride, 1-capric acid-2,3-dilauric acid glyceride and 1,3-dilauric acid-2-capric acid-glyceride; the capric lauric acid diglyceride is selected from at least one of 1-capric acid-3-lauric acid glyceride, 1-capric acid-2-lauric acid glyceride and 2-capric acid-1-lauric acid glyceride.

[0013] The present application also provides a method for preparing a medium-chain fatty acid mixed structure lipid, comprising:

[0014] Capric acid, lauric acid and glycerol are mixed at 55-75°C, and after being fully liquefied and mixed, immobilized lipase or chemical catalyst is added, vacuum is drawn or molecular sieves are added, and the mixture is kept warm for 4-12 hours. After filtering out solids, unreacted fatty acids and glycerol are removed by molecular distillation or chemical separation to obtain the medium-chain fatty acid mixed structure lipid. The molar ratio of capric acid, lauric acid and glycerol is (1-15): (1-15): 4.

[0015] Optionally, the mixing molar ratio of capric acid, lauric acid and glycerin is (2-8):(2-8):3.

[0016] The present application also provides a medium-chain fatty acid mixed structure lipid prepared by the preparation method.

[0017] Optionally, the capric lauric triglyceride is dicapric monolauric triglyceride and monocapric dilauric triglyceride; the capric lauric diglyceride is monocapric monolauric diglyceride.

[0018] Therefore, the present application also provides an application of a medium-chain fatty acid mixed structural fat in the preparation of a feed for improving systemic inflammation caused by a high-fat feed. The medium-chain fatty acid mixed structural fat contains, by mass percentage, 10-35% monolaurin monocaprate, 15-30% dilaurin monocaprate and 15-20% monolaurin monocaprate.

[0019] Optionally, the systemic inflammation caused by a high-fat diet may be an abnormal change in the level of at least one of pro-inflammatory cytokines, anti-inflammatory cytokines and inflammatory gene expressions caused by a high-fat diet; correspondingly, the improvement of the systemic inflammation caused by a high-fat diet may be the realization of at least one of the functions of reducing pro-inflammatory cytokines, increasing anti-inflammatory cytokines and improving inflammatory gene expression.

[0020] Optionally, the systemic inflammation includes abnormal changes in the levels of inflammatory factors IL-6, TNF-α, LPS, MCP-1 and IL-10 in serum.

[0021] Optionally, the improvement of inflammation caused by a high-fat diet refers to reducing the levels of IL-6, TNF-α, LPS and MCP-1 in the serum of animals fed a high-fat diet and increasing the level of IL-10 in the serum of animals fed a high-fat diet.

[0022] Optionally, the high-fat feed generally refers to a feed with a fat energy supply ratio exceeding 35% or a fat energy supply ratio within the range of 35-70%, for example, it may be a high-fat feed with a fat energy supply ratio of 45%.

[0023] The present application also provides an application of a medium-chain fatty acid mixed structural fat in the preparation of a feed for improving the microbial environment of intestinal flora, wherein the medium-chain fatty acid mixed structural fat contains 10-35% monolaurin monocaprate, 15-30% dilaurin monocaprate and 15-20% monolaurin monocaprate.

[0024] The present application also provides an application of a medium-chain fatty acid mixed structural fat in the preparation of a feed for increasing the abundance of D. cerevisiae in intestinal flora, wherein the medium-chain fatty acid mixed structural fat contains 10-35% monolaurin monocaprate, 15-30% dilaurin monocaprate and 15-20% monolaurin monocaprate.

[0025] Optionally, the monocapric dilaurin is selected from at least one of 1-capric acid-2,3-dilaurin and 2-capric acid-1,3-dilaurin;

[0026] The dicaprylic acid monolaurin glyceryl is selected from at least one of 1,2-dicaprylic acid-3-lauric acid glyceryl and 1,3-dicaprylic acid-2-lauric acid glyceryl;

[0027] The monocapric monolauric diglyceride is selected from at least one of 1-capric-3-lauric diglyceride, 1-capric-2-lauric diglyceride and 2-capric-1-lauric diglyceride.

[0028] Furthermore, the medium-chain fatty acid mixed structure lipid contains, by mass percentage:

[0029] 10-35% dilaurin monocaprate (preferably 1,3-dilaurin-2-caprate);

[0030] 15-30% glyceryl monolaurate dicaprate (preferably 1,3-glyceryl monolaurate dicaprate);

[0031] 15-20% monocapryloylglycerol monolaurate (preferably 1-capryloyl-3-laurylglyceride).

[0032] Optionally, the medium-chain fatty acid mixed structured lipid is added to a high-fat feed at 100-3000 mg / kg.

[0033] Furthermore, the medium-chain fatty acid mixed structured lipid is added to the high-fat feed at 200-1500 mg / kg.

[0034] The present application also provides a method for preparing a medium-chain fatty acid mixed structure lipid, comprising:

[0035] Capric acid, lauric acid and glycerol are subjected to esterification reaction to synthesize a medium-chain fatty acid mixed structure lipid containing 10-35% of monocapric dilaurin, 15-30% of dicapric monolaurin and 15-20% of monocapric monolaurin diglyceride in terms of mass percentage.

[0036] Optionally, the esterification reaction refers to a process in which fatty acids and alcohols react under the catalysis of acid, base or enzyme to generate ester compounds.

[0037] Optionally, when the esterification reaction occurs, the molar ratio of capric acid, lauric acid and glycerol is (1-15): (1-15): 4. Preferably, the molar ratio of capric acid, lauric acid and glycerol is (2-8): (2-8): 3. More preferably, the molar ratio of capric acid, lauric acid and glycerol is 2:1:1 (SDL) or 1:2:1 (SLD), and the content of capric acid lauric acid structured fat in the mixed structured fat synthesized under this condition is higher.

[0038] Optionally, the amount of immobilized lipase added during the esterification reaction is 4-12% of the substrate mass. The immobilized lipase used is any one of immobilized Aspergillus oryzae lipase, Rhizopus oryzae lipase and Rhizopus miehei lipase.

[0039] Optionally, the steps of the esterification reaction are as follows: the reactants are mixed at 55-75° C., and after being fully liquefied and mixed, immobilized lipase is added, vacuum is applied or molecular sieves are added, and the mixture is kept warm for 4-10 hours. After removing the solids, a capric acid lauric acid mixed structure lipid is obtained.

[0040] The present application also provides a medium-chain fatty acid mixed structure lipid prepared by the preparation method.

[0041] Compared with the prior art, the present invention has at least one of the following advantages:

[0042] (1) The content of capric lauric acid structural fat in the product is higher than 55%;

[0043] (2) increase the abundance of intestinal Dunaliella;

[0044] (3) Improve systemic inflammation. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 This is the result diagram of the effect of capric acid and lauric acid mixed structure lipids on serum inflammatory factors;

[0046] Figure 2 This is the result diagram of the effect of the mixed structural lipid of capric acid and lauric acid on the abundance of Dunaliella;

[0047] Figure 3 This is a graph showing the effect of capric acid and lauric acid mixed structured lipids on the expression of liver inflammatory genes. DETAILED DESCRIPTION

[0048] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0050] A capric lauric acid mixed structure fat, its components include: capric lauric acid triglyceride and capric lauric acid diglyceride, the molar ratio of capric acid to lauric acid is 1:4-4:1. Capric lauric acid triglyceride is dicapric acid monolauric acid triglyceride and monocapric acid dilauric acid triglyceride, and capric lauric acid diglyceride is monocapric acid monolauric acid diglyceride. Further, the capric lauric acid triglyceride can be selected from at least one of 1,2-dicapric acid-3-lauric acid glyceride, 1,3-dicapric acid-2-lauric acid glyceride, 1-capric acid-2,3-dilauric acid glyceride and 1,3-dilauric acid-2-capric acid-glyceride, and capric lauric acid diglyceride can be selected from at least one of 1-capric acid-3-lauric acid glyceride, 1-capric acid-2-lauric acid glyceride and 2-capric acid-1-lauric acid glyceride.

[0051] In one embodiment, a capric acid lauric acid mixed structural fat comprises, by mass percentage, 10-35% of monocapric dilaurin, 15-30% of dicapric monolaurin and 15-20% of monocapric monolaurin diglyceride. Wherein, monocapric dilaurin is selected from at least one of 1-capric acid-2,3-dilaurin and 2-capric acid-1,3-dilaurin; dicapric monolaurin is selected from at least one of 1,2-capric acid-3-laurin and 1,3-capric acid-2-laurin; and monocapric monolaurin diglyceride is selected from at least one of 1-capric acid-3-laurin, 1-capric acid-2-laurin and 2-capric acid-1-laurin.

[0052] A method for synthesizing the above-mentioned mixed structure lipid comprises: esterification reaction of capric acid, lauric acid and glycerol to synthesize capric acid lauric acid mixed structure lipid; the esterification reaction refers to the process of generating ester compounds by the reaction of fatty acids and alcohols under the catalysis of acid, alkali or enzyme.

[0053] When the esterification reaction occurs, the molar ratio of capric acid, lauric acid and glycerol is (1-15): (1-15): 4. Preferably, the molar ratio of capric acid, lauric acid and glycerol is (2-8): (2-8): 3. More preferably, the molar ratio of capric acid, lauric acid and glycerol is 2:1:1 (SDL) or 1:2:1 (SLD). Under this condition, the content of capric acid lauric acid structured fat in the synthesized mixed structured fat is higher.

[0054] The amount of immobilized lipase added to the reaction is 4-12% of the substrate mass. The immobilized lipase used is any one of immobilized Aspergillus oryzae lipase, Rhizopus oryzae lipase and Rhizopus miehei lipase, all of which can be purchased commercially.

[0055] The steps of the esterification reaction are as follows: the reactants are mixed at 55-75° C., and after being fully liquefied and mixed, immobilized lipase is added, vacuum is drawn or molecular sieves are added, and the mixture is kept warm for 4-10 hours. After the solids are removed, a capric acid lauric acid mixed structure lipid is obtained.

[0056] Application of the above-mentioned mixed structural lipids in improving systemic inflammation induced by a high-fat diet: In some instances, at least one of the following needs to be met: at least one of the functions of reducing pro-inflammatory cytokines, increasing anti-inflammatory cytokines, and improving inflammatory gene expression is achieved.

[0057] Application of the above mixed structural lipids in improving intestinal health: In some instances, at least one of the following needs to be met: increasing the abundance of intestinal flora, improving the structure of intestinal flora, and increasing the abundance of Dunaliella.

[0058] The capric lauric acid mixed structural lipids SDL and SLD were synthesized by the above method, and tricaprin and trilaurin with the same fatty acid molar ratio were used as the corresponding physical mixed oils MDL and MLD. The efficacy of mixed structural lipids in improving inflammation and intestinal health was evaluated by animal experiments. C57BL / 6J mice were randomly divided into groups, 10 in each group, with free diet and water, and samples were taken after 16 weeks. The control group was fed with ordinary feed (fat energy ratio of 10%), the high-fat group was fed with high-fat feed (fat energy ratio of 45%), experimental group 1 was fed with high-fat feed supplemented with 300-2400 mg / kg SDL, experimental group 2 was fed with high-fat feed supplemented with 300-2400 mg / kg MDL, experimental group 3 was fed with high-fat feed supplemented with 300-2400 mg / kg SLD, and experimental group 4 was fed with high-fat feed supplemented with 300-2400 mg / kg MLD.

[0059] High-fat feed with a fat energy supply ratio of 45% is a relatively common high-fat feed. Therefore, the following examples use MD12032 high-fat feed from Jiangsu Medison Biopharmaceutical Co., Ltd. The comparison between the high-fat feed and the ordinary feed is as follows:

[0060]

[0061] Other raw materials are also commercially available.

[0062] Example 1: Synthesis of capric acid and lauric acid mixed structure lipid

[0063] Capric acid, lauric acid and glycerol were mixed in a molar ratio of 1:2:1 and 2:1:1, respectively, placed in a 65°C constant temperature water bath shaker, completely melted and mixed, and then 10% of the substrate mass of immobilized lipase (immobilized Aspergillus oryzae lipase) and an appropriate amount (about 20% of the substrate mass) of molecular sieves were added, covered with a flip stopper, reacted at 200rpm for 6h, and then filtered to remove the lipase and molecular sieves. The product was dissolved in n-hexane, phenolphthalein was used as an indicator, and KOH methanol solution was titrated to pink, excess fatty acids were removed, and n-hexane was removed by rotary evaporation to obtain a capric acid lauric acid mixed structure lipid.

[0064] Weigh an appropriate amount of the above mixed structural lipids and identify the components by GC-MS. The composition is shown in Table 1 (corresponding to 1:2:1) and Table 2 (corresponding to 2:1:1).

[0065] Table 1 Composition of capric acid lauric acid mixed structure lipid (SDL) (the molar ratio of capric acid to lauric acid in the mixed structure lipid is 1.7:1)

[0066]

[0067] Table 2 Composition of capric acid lauric acid mixed structure fat (SLD) (the molar ratio of capric acid to lauric acid in the mixed structure fat is 1:2.3)

[0068]

[0069] “Others” usually refers to detected impurities that are not target compounds.

[0070] Example 2: Capric and lauric acid mixed structured lipids increase the abundance of Dunaliella in the intestinal flora and improve systemic inflammation induced by a high-fat diet

[0071] The capric lauric acid mixed structured lipids SDL and SLD were synthesized by Example 1, and tricaprin and trilaurin with the same fatty acid molar ratio were used as the corresponding physical mixed oils MDL and MLD. The efficacy of the mixed structured lipids in improving inflammation and intestinal health was evaluated by animal experiments, and C57BL / 6J mice were randomly divided into groups, 10 in each group, with free diet and water, and samples were taken after 16 weeks.

[0072] The groups are as follows:

[0073] (1) Control group (NCD): normal diet (10% fat energy supply)

[0074] (2) High-fat diet (HFD): high-fat diet (fat energy ratio is 45%)

[0075] (3) Experimental group 1 (SDL): high-fat diet + 1200 mg / kg SDL

[0076] (4) Experimental group 2 (MDL): high-fat diet + 1200 mg / kg MDL

[0077] (5) Experimental group 3 (SLD): high-fat diet + 1200 mg / kg SLD

[0078] (6) Experimental group 4 (MLD): high-fat diet + 1200 mg / kg MLD.

[0079] The high-fat diets in experimental groups 1 to 4 were the same as those in the high-fat group.

[0080] After 16 weeks, the mice were fasted overnight, and fresh blood was collected by orbital bleeding. After standing for 30 minutes, the blood was centrifuged to obtain serum, which was stored at -80°C.

[0081] Elisa method was used to measure the levels of inflammatory factors in serum. Figure 1 As shown, A to E in the figure are the effect results of IL-6, IL-10, TNF-α, LPS and MCP-1 respectively:

[0082] Compared with the control group (NCD), the high-fat diet (HFD) increased the levels of IL-6, TNF-α, LPS and MCP-1 in serum, and decreased the level of IL-10. The capric lauric acid mixed structural lipid and the corresponding physical mixed oil can significantly reduce the serum IL-6 level, and the effect of the capric lauric acid mixed structural lipid is more significant than that of the physical mixed oil. The serum IL-10 levels of the SDL, MDL and SLD groups were significantly higher than those of the HFD group, while there was no significant difference between the MLD group and the HFD group. SDL and MDL significantly reduced the serum TNF-α level. Although the SLD group had no statistically significant difference from the HFD group, there was a trend to reduce the TNF-α level (P=0.07). SDL, MDL, and SLD significantly reduced the serum LPS level, and MLD had a trend to reduce LPS (P=0.06). SDL, SLD and MLD significantly improved the increase of MCP-1 induced by high fat.

[0083] The above results show that both the capric acid-lauric acid mixed structural lipid and its corresponding physical mixed oil have the effect of improving high-fat-induced systemic inflammation, and the effect of the capric acid-lauric acid mixed structural lipid is stronger than the corresponding physical mixed oil, while the ratio of capric acid and lauric acid in the mixed structural lipid has little effect on its anti-inflammatory effect.

[0084] The ileum contents of mice were collected for 16S RNA sequencing analysis, and the abundance of Dunaliella was as follows: Figure 2 As shown:

[0085] Compared with the NCD group, the abundance of Bacillus subtilis in the HFD group was significantly reduced, while SDL, MDL and SLD all had a significant improvement effect on this, indicating that the mixed structural lipid of capric acid and lauric acid can increase the abundance of Bacillus subtilis, among which the effect of SDL is more significant.

[0086] mRNA was extracted from mouse liver, reverse transcribed and then amplified by PCR. Figure 3 As shown, A to D in the figure are the results of the effects of IL-6, IL-10, TNF-α and TLR4 respectively:

[0087] High-fat feeding significantly changed the expression of inflammatory genes in the liver. Compared with the NCD group, the expression levels of IL-6, TNF-α and TLR4 in the liver of the HFD group were significantly increased, and the expression of IL-10 was decreased. Although the physical mixed oils (MDL and MLD) can improve the high-fat-induced increase in IL-6 and TNF-α, the effects on IL-10 and TLR4 are not obvious. SDL significantly improved the expression of IL-6, TNF-α and IL-10, and had no significant effect on the expression of TLR4. SLD has a significant improvement effect on the expression of IL-6, TNF-α, IL-10 and TLR4. This shows that the two capric lauric acid mixed structural lipids provided in this case have a good improvement effect on inflammation, and the effect of SLD is more significant.

[0088] From the comparison of the above results, it can be seen that in terms of serum inflammatory indicators, physical mixed oils MDL and MLD can improve some indicators, while SDL and SLD have an improvement effect on all indicators, and are more significant than physical mixed oils. In terms of gene expression, MDL has no significant effect on the expression of TLR4 and IL-10, and MLD has no significant effect on the expression of IL-10, while SDL and SLD can significantly improve the expression of IL-6, IL-10 and TNF-α, and the effect of SLD is more significant. In terms of the abundance of Ducromatella, both MDL and SDL significantly increase the abundance of Ducromatella, and there is no obvious difference between the two, but MLD has no significant effect on the abundance of Ducromatella, while the corresponding SLD can significantly increase the abundance of Ducromatella.

[0089] The above results indicate that the capric acid and lauric acid mixed structural lipid of the present application can increase the abundance of Ducromatium and improve the systemic inflammation induced by a high-fat diet under long-term action of 16 weeks, and the effect is stronger than that of the physical mixed oil.

[0090] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims.

Claims

1. Use of medium-chain fatty acid mixed structure lipid in preparing feed for improving systemic inflammation caused by high-fat feed, characterized in that: The medium-chain fatty acid mixed structure fat contains capric lauric acid triglyceride and capric lauric acid diglyceride; the molar ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structure fat is 1:4-4:

1.

2. Use of medium-chain fatty acid mixed structure lipids in the preparation of feed for improving the microbial environment of intestinal flora, characterized in that: The medium-chain fatty acid mixed structure fat contains capric lauric acid triglyceride and capric lauric acid diglyceride; the molar ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structure fat is 1:4-4:

1.

3. Use of medium-chain fatty acid mixed structure lipids in the preparation of feed for increasing the abundance of Ducromatella in intestinal flora, characterized in that: The medium-chain fatty acid mixed structure fat contains capric lauric acid triglyceride and capric lauric acid diglyceride; the molar ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structure fat is 1:4-4:

1.

4. The use according to any one of claims 1 to 3, characterized in that: The capric lauric acid triglyceride is selected from at least one of 1,2-dicapric acid-3-lauric acid glyceride, 1,3-dicapric acid-2-lauric acid glyceride, 1-capric acid-2,3-dilauric acid glyceride and 1,3-dilauric acid-2-capric acid-glyceride; the capric lauric acid diglyceride is selected from at least one of 1-capric acid-3-lauric acid glyceride, 1-capric acid-2-lauric acid glyceride and 2-capric acid-1-lauric acid glyceride.

5. The use according to claim 4, characterized in that: The capric lauric acid triglyceride is a mixture of 1,3-dilauric acid-2-capric acid-glyceride and 1,3-dicapric acid-2-lauric acid glyceride; the capric lauric acid diglyceride is 1-capric acid-3-lauric acid glyceride.

6. The use according to any one of claims 1 to 3, characterized in that: The medium-chain fatty acid mixed structural lipid is added into high-fat feed at 100-3000 mg / kg.

7. A medium-chain fatty acid mixed structure lipid, characterized in that: The medium-chain fatty acid mixed structure fat contains capric lauric acid triglyceride and capric lauric acid diglyceride; the molar ratio of capric acid to lauric acid in the medium-chain fatty acid mixed structure fat is 1:4-4:

1.

8. The medium-chain fatty acid mixed structure lipid according to claim 6, characterized in that: The capric lauric acid triglyceride is selected from at least one of 1,2-dicapric acid-3-lauric acid glyceride, 1,3-dicapric acid-2-lauric acid glyceride, 1-capric acid-2,3-dilauric acid glyceride and 1,3-dilauric acid-2-capric acid-glyceride; the capric lauric acid diglyceride is selected from at least one of 1-capric acid-3-lauric acid glyceride, 1-capric acid-2-lauric acid glyceride and 2-capric acid-1-lauric acid glyceride.

9. A method for preparing a medium-chain fatty acid mixed structure lipid, characterized in that: include: Capric acid, lauric acid and glycerol are mixed at 55-75° C., and after they are fully liquefied and mixed, immobilized lipase or chemical catalyst is added, vacuum is applied or molecular sieves are added, and the mixture is kept warm for 4-12 hours. After the solids are removed by filtration, unreacted fatty acids and glycerol are removed by molecular distillation or chemical separation to obtain the medium-chain fatty acid mixed structure lipid.

10. A medium-chain fatty acid mixed structure lipid prepared by the preparation method according to claim 9.

Citation Information

Patent Citations

  • Slow-release butyric acid and lauric acid ester as well as preparation method and application thereof

    CN113768047A

  • Breast milk-like OMO type structural ester and preparation method thereof

    CN114907209A

  • Genetically engineered bacterium for producing OPO type structural ester as well as construction method and application of genetically engineered bacterium

    CN116179381A

Cited By

  • Use of medium-chain fatty acid mixed structured lipid in amelioration of dietary-induced glucose-lipid metabolism disorder

    WO2026031739A1

  • Fatty acid triglycerides for cognitive health

    WO2026198444A1